Key clinical point: A personalized neoantigen vaccine appears safe and active in patients with non–small cell lung cancer.
Major finding: The neoantigen vaccine produced only grade 1 adverse events and yielded responses in seven patients, including one complete response.
Study details: Phase 1b trial of 24 patients with NSCLC.
Disclosures: The trial is sponsored by Tianjin Beichen Hospital and funded by Tianjin HengJia Biotechnology Development Co. Ltd. Dr. Lizee disclosed a consulting relationship with Tianjin HengJia Biotechnology Development Co. Ltd.
Lizee G et al. SITC 2019. Abstract O18.